

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Caput et al.

Serial No.: 09/125,005

Filed: July 30, 1998

Group Art Unit: 1642

Examiner: Ungar, S.

For: PURIFIED SR-p70 PROTEIN

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

**RESPONSE**

This is responsive to the Office Action mailed April 12, 2000 in the above-identified application setting a one-month period for response. Pursuant to the Petition for Extension of Time Under 37 C.F.R. § 1.136(a) submitted herewith the due date for response is extended to August 12, 2000. This response is therefore timely.

Claims 1-38 are in the application. Restriction is required under 35 U.S.C. § 121 among 117 Groups variously directed to polypeptides, polynucleotides, primers/probes and methods of use thereof in therapeutic treatment and diagnosis, each of said Groups apparently representing what the Examiner considers to be a separate and distinct invention.



**CERTIFICATE UNDER 37 C.F.R. 1.8(a)**

I hereby certify that this correspondence is being deposited on the date indicated below with the United States Postal Service as first class mail addressed to:

Assistant Commissioner for Patents,  
Washington, DC 20231.

Name

*Paula S. Ocker*

Date

*August 9, 2000*

*RECEIVED*  
AUG 23 2000  
TELE CENTER 160023000

*H*  
*11*  
*RD*  
*8-29-00*

Applicants hereby elect for prosecution the Examiner's Group 3, the polypeptide of SEQ ID No. 6 which is read on by claims 1-6, 25 and 33-36.

Dated: August 9, 2000

Sanofi-Synthelabo Inc.  
Patent Department  
9 Great Valley Parkway  
P.O. Box 3026  
Malvern, PA 19355  
Tel.: (610) 889-6338  
Fax: (610) 889-8799



Respectfully submitted,

  
PAUL E. DUPONT  
Registration No. 27,438